Literature DB >> 34586464

The prevalence and clinical correlates of metabolic syndrome and cardiometabolic alterations in 430 drug-naive patients in their first episode of schizophrenia.

Xiaoe Lang1, Qinqin Liu2, Hanliu Fang2, Yongjie Zhou3, Mattew T Forster4, Zezhi Li5, Xiangyang Zhang6,7.   

Abstract

RATIONALE: Although metabolic abnormalities and metabolic syndrome (MetS) have been extensively investigated in schizophrenia, few studies have examined them in first-episode drug-naive (FEDN) patients.
OBJECTIVES: This study aimed to investigate the prevalence and clinical correlates of metabolic abnormalities in FEDN schizophrenia patients.
METHODS: A total of 430 FEDN schizophrenia patients and 453 controls were recruited. Various parameters were measured including BMI, waist circumference, blood pressure, lipid profiles, blood glucose, glycosylated hemoglobin (HbA1c), insulin, and homeostatic model assessment for insulin resistance (HOMA-IR).
RESULTS: Patients had a higher prevalence of MetS, hypertension, hypertriglyceridemia, hypo-HDL-C, elevated HAb1c, and elevated insulin than controls (19.1% vs. 6.6%, OR = 2.52; 33.3% vs. 12.1%, OR = 3.05; 30.5% vs. 16.1%, OR = 2.25; 43.1% vs. 24.0%, OR = 2.21; 25.6% vs. 10.8%, OR = 2.62; 9.1% vs. 0.9%, OR = 10.29; all pBonferroni < 0.001). Waist circumference was associated with PANSS general psychopathology and total score (correlation coefficient r = 0.17, pBonferroni < 0.001; correlation coefficient r = 0.16, pBonferroni = 0.004). Fasting glucose was associated with PANSS negative, general psychopathology, and total score (correlation coefficient r = 0.13, pBonferroni = 0.03; correlation coefficient r = 0.19, pBonferroni < 0.001; correlation coefficient r = 0.20, pBonferroni < 0.001). BMI (OR = 1.37), smoking (OR = 3.39), and HOMA-IR (OR = 5.60) were associated with MetS in FEDN schizophrenia (all p < 0.001).
CONCLUSIONS: Our results demonstrate that MetS and metabolic abnormalities co-existed in the early stages of schizophrenia without antipsychotics. Waist circumference and glucose were associated with psychopathological symptoms, while BMI, smoking, and HOMA-IR were associated with MetS in FEDN schizophrenia.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Metabolic abnormalities; Metabolic syndrome; Schizophrenia

Mesh:

Substances:

Year:  2021        PMID: 34586464     DOI: 10.1007/s00213-021-05983-9

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  39 in total

1.  Twenty-five year mortality of a community cohort with schizophrenia.

Authors:  Steve Brown; Miranda Kim; Clemence Mitchell; Hazel Inskip
Journal:  Br J Psychiatry       Date:  2010-02       Impact factor: 9.319

2.  Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: an analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort.

Authors:  Julio Bobes; Celso Arango; Margarida Garcia-Garcia; Javier Rejas
Journal:  Schizophr Res       Date:  2010-03-09       Impact factor: 4.939

3.  Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome.

Authors:  Tony Cohn; Denis Prud'homme; David Streiner; Homa Kameh; Gary Remington
Journal:  Can J Psychiatry       Date:  2004-11       Impact factor: 4.356

4.  [The prevalence of metabolic syndrome and related factors in patients with schizophrenia].

Authors:  Cem Cerit; Eylem Ozten; Mustafa Yildiz
Journal:  Turk Psikiyatri Derg       Date:  2008

5.  Adiponectin as a potential biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia.

Authors:  Ya Mei Bai; Jen-Yeu Chen; Wei-Shiung Yang; Yu-Chiao Chi; Ying-Jay Liou; Chao-Cheng Lin; Ying-Chieh Wang; Chih-Yuan Lin; Tung-Pine Su; Pesus Chou
Journal:  J Clin Psychiatry       Date:  2007-12       Impact factor: 4.384

6.  Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication.

Authors:  Marc A De Hert; Ruud van Winkel; Dominique Van Eyck; Linda Hanssens; Martien Wampers; Andre Scheen; Joseph Peuskens
Journal:  Schizophr Res       Date:  2006-02-14       Impact factor: 4.939

Review 7.  Metabolic issues in psychotic disorders with the focus on first-episode patients: a review.

Authors:  Dubravka Britvic; Nadja P Maric; Mirjana Doknic; Sandra Pekic; Sanja Andric; Miroslava Jasovic-Gasic; Vera Popovic
Journal:  Psychiatr Danub       Date:  2013-12       Impact factor: 1.063

8.  Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors.

Authors:  Ole A Andreassen; Srdjan Djurovic; Wesley K Thompson; Andrew J Schork; Kenneth S Kendler; Michael C O'Donovan; Dan Rujescu; Thomas Werge; Martijn van de Bunt; Andrew P Morris; Mark I McCarthy; J Cooper Roddey; Linda K McEvoy; Rahul S Desikan; Anders M Dale
Journal:  Am J Hum Genet       Date:  2013-01-31       Impact factor: 11.025

9.  Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study.

Authors:  M De Hert; R van Winkel; D Van Eyck; L Hanssens; M Wampers; A Scheen; J Peuskens
Journal:  Clin Pract Epidemiol Ment Health       Date:  2006-06-27

10.  Insulin Resistance and Its Association with Metabolic Syndrome in Korean Children.

Authors:  Jinkyung Cho; Haeryun Hong; Soohyun Park; Shinuk Kim; Hyunsik Kang
Journal:  Biomed Res Int       Date:  2017-12-31       Impact factor: 3.411

View more
  3 in total

1.  Influencing factors of obesity in community patients with deficit schizophrenia: a cross-sectional study.

Authors:  Na Yong; Jiyang Pan; Xuehua Li; Ling Yu; Xin Hou
Journal:  Eur J Med Res       Date:  2022-06-11       Impact factor: 4.981

Review 2.  Crosstalk between Schizophrenia and Metabolic Syndrome: The Role of Oxytocinergic Dysfunction.

Authors:  Kah Kheng Goh; Cynthia Yi-An Chen; Tzu-Hua Wu; Chun-Hsin Chen; Mong-Liang Lu
Journal:  Int J Mol Sci       Date:  2022-06-25       Impact factor: 6.208

3.  Shared genetic components between metabolic syndrome and schizophrenia: Genetic correlation using multipopulation data sets.

Authors:  Rei Aoki; Takeo Saito; Kohei Ninomiya; Ayu Shimasaki; Takuma Ashizawa; Kenta Ito; Masashi Ikeda; Nakao Iwata
Journal:  Psychiatry Clin Neurosci       Date:  2022-05-30       Impact factor: 12.145

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.